[HTML][HTML] DOCK2 is involved in the host genetics and biology of severe COVID-19
…, N Takayanagi, S Ueda, A Tada, M Miyawaki… - Nature, 2022 - nature.com
Identifying the host genetic factors underlying severe COVID-19 is an emerging challenge 1
, 2 , 3 , 4 – 5 . Here we conducted a genome-wide association study (GWAS) involving 2,393 …
, 2 , 3 , 4 – 5 . Here we conducted a genome-wide association study (GWAS) involving 2,393 …
[HTML][HTML] In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
…, A Oashi, K Ishioka, D Arai, S Nukaga, M Miyawaki… - Oncotarget, 2015 - ncbi.nlm.nih.gov
EGFR mutated lung cancer accounts for a significant subgroup of non-small-cell lung cancer
(NSCLC). Over the last decade, multiple EGFR tyrosine kinase inhibitors (EGFR-TKIs) have …
(NSCLC). Over the last decade, multiple EGFR tyrosine kinase inhibitors (EGFR-TKIs) have …
Overcoming EGFR bypass signal-induced acquired resistance to ALK tyrosine kinase inhibitors in ALK-translocated lung cancer
Activation of the EGFR pathway is one of the mechanisms inducing acquired resistance to
anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) such as crizotinib and …
anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) such as crizotinib and …
[HTML][HTML] The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force
…, N Takayanagi, S Ueda, A Tada, M Miyawaki… - Nature …, 2022 - nature.com
Coronavirus disease 2019 (COVID-19) is a recently-emerged infectious disease that has
caused millions of deaths, where comprehensive understanding of disease mechanisms is still …
caused millions of deaths, where comprehensive understanding of disease mechanisms is still …
Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
…, D Arai, K Ishioka, K Ohgino, M Miyawaki… - Molecular cancer …, 2016 - AACR
Alectinib is a highly selective ALK inhibitor and shows promising efficacy in non–small cell
lung cancers (NSCLC) harboring the EML4-ALK gene rearrangement. The precise …
lung cancers (NSCLC) harboring the EML4-ALK gene rearrangement. The precise …
[HTML][HTML] Impact of respiratory bacterial infections on mortality in Japanese patients with COVID-19: a retrospective cohort study
…, T Yoshiyama, K Kataoka, Y Mutoh, M Miyawaki… - BMC Pulmonary …, 2023 - Springer
Background Although cases of respiratory bacterial infections associated with coronavirus
disease 2019 (COVID-19) have often been reported, their impact on the clinical course …
disease 2019 (COVID-19) have often been reported, their impact on the clinical course …
Comprehensive analysis of long COVID in a Japanese nationwide prospective cohort study
…, H Kokuto, T Kusumoto, A Oashi, M Miyawaki… - Respiratory …, 2023 - Elsevier
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread
rapidly since 2019, and the number of reports regarding long COVID has increased. Although …
rapidly since 2019, and the number of reports regarding long COVID has increased. Although …
Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan
…, N Takayanagi, S Ueda, A Tada, M Miyawaki… - Medrxiv, 2021 - medrxiv.org
To elucidate the host genetic loci affecting severity of SARS-CoV-2 infection, or Coronavirus
disease 2019 (COVID-19), is an emerging issue in the face of the current devastating …
disease 2019 (COVID-19), is an emerging issue in the face of the current devastating …
Long-term survival of a patient with small cell lung cancer secreting ADH and ACTH simultaneously, following the prolonged use of amrubicin
…, T Shirahata, N Kudo, Y Uehara, M Miyawaki… - Internal …, 2020 - jstage.jst.go.jp
Paraneoplastic syndromes are frequently observed in lung cancer, especially in small cell
lung cancer (SCLC). Although there have been many reports on paraneoplastic syndromes, …
lung cancer (SCLC). Although there have been many reports on paraneoplastic syndromes, …
[HTML][HTML] Erlotinib as second‑or third‑line treatment in elderly patients with advanced non‑small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)
M Miyawaki, K Naoki, S Yoda… - Molecular and …, 2017 - spandidos-publications.com
The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second‑or third‑line treatment for …
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second‑or third‑line treatment for …
